Literature DB >> 32694342

Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study.

Maria L Muiesan1, Massimo Salvetti1, Agostino Virdis2, Stefano Masi2, Edoardo Casiglia3,4, Valérie Tikhonoff3,4, Carlo M Barbagallo5, Michele Bombelli6, Arrigo F G Cicero7, Massimo Cirillo8, Pietro Cirillo9, Giovambattista Desideri10, Lanfranco D'Eliak11, Claudio Ferri10, Ferruccio Galletti11, Loreto Gesualdo9, Cristina Giannattasio12,13, Guido Iaccarino14, Francesca Mallamaci15, Alessandro Maloberti12,13, Alberto Mazza16, Pietro Nazzaro17, Paolo Palatini3,4, Gianfranco Parati18, Roberto Pontremoli19, Marcello Rattazzi3,4,20, Giulia Rivasi21, Giuliano Tocci22,23, Andrea Ungar21, Paolo Verdecchia24, Francesca Viazzi19, Massimo Volpe22, Guido Grassi6, Claudio Borghi7.   

Abstract

OBJECTIVE: To assess the prognostic cut-off values of serum uric acid (SUA) in predicting fatal and morbid heart failure in a large Italian cohort in the frame of the Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension.
METHODS: The URic acid Right for heArt Health (URRAH) study is a nationwide, multicentre, cohort study involving data on individuals aged 18-95 years, recruited on a community basis from all regions of Italy under the patronage of the Italian Society of Hypertension with a mean follow-up period of 128 ± 65 months. Incident heart failure was defined on the basis of International Classification of Diseases Tenth Revision codes and double-checked with general practitioners and hospital files. Multivariate Cox regression models having fatal and morbid heart failure as dependent variables, adjusted for sex, age, SBP, diabetes, estimated glomerular filtration rate, smoking habit, ethanol intake, BMI, haematocrit, LDL cholesterol, previous diagnosis of heart failure and use of diuretics as possible confounders, were used to search for an association between SUA as a continuous variable and heart failure. By means of receiver operating characteristic curves, two prognostic cut-off values (one for all heart failure and one for fatal heart failure) were identified as able to discriminate between individuals doomed to develop the event. These cut-off values were used as independent predictors to divide individuals according to prognostic cut-off values in a multivariate Cox models, adjusted for confounders.
RESULTS: A total of 21 386 individuals were included in the analysis. In Cox analyses, SUA as a continuous variable was a significant predictor of all [hazard ratio 1.29 (1.23-1.359), P < 0.0001] and fatal [hazard ratio 1.268 (1.121-1.35), P < 0.0001] incident heart failure. Cut-off values of SUA able to discriminate all and fatal heart failure status were identified by mean of receiver operating characteristic curves in the whole database: SUA more than 5.34 mg/dl (confidence interval 4.37-5.6, sensitivity 52.32, specificity 63.96, P < 0.0001) was the univariate prognostic cut-off value for all heart failure, whereas SUA more than 4.89 mg/dl (confidence interval 4.78-5.78, sensitivity 68.29, specificity 49.11, P < 0.0001) for fatal heart failure. The cut-off for all heart failure and the cut-off value for fatal heart failure were accepted as independent predictors in the Cox analysis models, the hazard ratios being 1.645 (1.284-2.109, P < 0.0001) for all heart failure and 1.645 (1.284-2.109, P < 0.0001) for fatal heart failure, respectively.
CONCLUSION: The results of the current study confirm that SUA is an independent risk factor for all heart failure and fatal heart failure, after adjusting for potential confounding variables and demonstrate that a prognostic cut-off value can be identified for all heart failure (>5.34 mg/dl) and for fatal heart failure (>4.89 mg/dl).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32694342     DOI: 10.1097/HJH.0000000000002589

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

1.  Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update.

Authors:  Claudio Borghi; Justyna Domienik-Karłowicz; Andrzej Tykarski; Krystyna Widecka; Krzysztof J Filipiak; Miłosz J Jaguszewski; Krzysztof Narkiewicz; Giuseppe Mancia
Journal:  Cardiol J       Date:  2021-01-13       Impact factor: 2.737

2.  Serum Uric Acid Levels and Cardiometabolic Profile in Middle-Aged, Treatment-Naïve Hypertensive Patients.

Authors:  Panagiotis Theofilis; Vasilis Tsimihodimos; Aikaterini Vordoni; Rigas G Kalaitzidis
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-05-07

Review 3.  Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.

Authors:  Arrigo F G Cicero; Federica Fogacci; Masanari Kuwabara; Claudio Borghi
Journal:  Medicina (Kaunas)       Date:  2021-01-10       Impact factor: 2.430

4.  Platelet Activity and Its Correlation with Inflammation and Cell Count Readings in Chronic Heart Failure Patients with Reduced Ejection Fraction.

Authors:  Aušra Mongirdienė; Jolanta Laukaitienė; Vilius Skipskis; Lolita Kuršvietienė; Julius Liobikas
Journal:  Medicina (Kaunas)       Date:  2021-02-18       Impact factor: 2.430

Review 5.  Uric Acid, Hypertensive Phenotypes, and Organ Damage: Data from the Pamela Study.

Authors:  Guido Grassi; Jennifer Vanoli; Rita Facchetti; Giuseppe Mancia
Journal:  Curr Hypertens Rep       Date:  2022-01-25       Impact factor: 5.369

6.  Architecture of a multi-channel and easy-to-make microfluidic paper-based colorimetric device (μPCD) towards selective and sensitive recognition of uric acid by AuNPs: an innovative portable tool for the rapid and low-cost identification of clinically relevant biomolecules.

Authors:  Fatemeh Farshchi; Arezoo Saadati; Mohammad Hasanzadeh; Farzad Seidi
Journal:  RSC Adv       Date:  2021-08-10       Impact factor: 4.036

7.  Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial.

Authors:  Nerea Becerra-Tomás; Miguel Ruiz-Canela; Pablo Hernández-Alonso; Mònica Bulló; Jun Li; Marta Guasch-Ferré; Estefanía Toledo; Clary B Clish; Ramon Estruch; Emilio Ros; Montserrat Fitó; Chih-Hao Lee; Kerry Pierce; Fernando Arós; Lluís Serra-Majem; Liming Liang; Cristina Razquin; Enrique Gómez-Gracia; Miguel A Martínez-González; Frank B Hu; Dolores Corella; Jordi Salas-Salvadó
Journal:  Metabolites       Date:  2021-05-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.